RSP Successfully Closes EUR 17 million Series C Capital Raise
We are proud to share that RSP Systems has successfully closed its Series C investment round at its hard cap of EUR 17 million. This capital injection will continue to support RSP’s fast-paced growth to delivering the world’s first non-invasive wearable glucose monitor. The financing round is the latest in a series of successful capital […]
Calibration of a non-invasive Raman spectroscopy device realized using pre-collected clinical data
Recent Clinical Results Revealed at ATTD 2024
At this year’s ATTD conference in Florence, RSP Systems shared recent findings from our latest clinical study, namely RSP-26, showcasing that non-invasive monitoring of glucose levels in people with type 2 diabetes is now possible and efficient following only a short initial calibration. Historically, the calibration stability and accuracy required for non-invasive glucose monitoring have […]
Explore Our Latest Innovation at ATTD 2024
From 6-9 March this year, RSP Systems will be participating in the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy. Our adept team present at this important event will include Anders Weber (CEO), Stine Dahl (CFO/COO), Kaspar Rasmussen (Senior Data Science Specialist) and Markus Rasmussen (Machine Learning Specialist). You will be able […]
Rapid Advancements in Technology Miniaturization
As pioneers within our field, we have successfully demonstrated the ability to monitor – completely non-invasively – and track glucose levels over an extended period of time 1,2. This breakthrough has not only expanded our knowledge but also enabled us to refine our technology, resulting in the miniaturisation of the individual components. We are now […]
Stine Holst Madsen
Lead Regulatory Affairs Specialist
Barbara Korzeniowska
Head of Clinical Research & Operations
Robert von Werz
Business Development & Investor Relations
